Emergent BioSolutions (EBS) Q4 2024 earnings summary

Executive summary

• Completed the first phase of a multi-year transformation plan ahead of schedule, focusing on debt reduction, profitability, and asset divestitures, with streamlined operations and leadership changes.

• Refocused core business on medical countermeasures (MCM) and Narcan nasal spray, maintaining ~75% market share and distributing 22 million doses in 2024.

• Resolved legacy legal and quality issues, improved compliance, and refinanced debt, extending maturity to 2029.

• Strategic actions included $117 million in asset sales, $50 million settlement from Janssen, and new contract wins supporting transformation.

• Net loss for 2024 was $190.6 million, a 75% improvement from 2023; adjusted EBITDA was $183 million, a turnaround from a loss in 2023.

Financial highlights

• FY 2024 total revenues were $1.04 billion, nearly flat year-over-year; Q4 2024 revenue was $195 million, with declines in Narcan and anthrax sales offset by higher smallpox sales.

• Adjusted EBITDA for FY 2024 was $183 million, up from $(22) million in 2023; Q4 adjusted EBITDA was $21 million, up $18 million year-over-year.

• Operating expenses for 2024 were $379 million, down 21% year-over-year, reflecting $130 million in annualized cost savings.

• Operating cash flow was $59 million, a $265 million improvement year-over-year; year-end liquidity was $200 million.

• Gross debt reduced to $700 million from $868 million; net debt at year-end 2024 was $601 million, a 21% reduction.

Outlook and guidance

• 2025 revenue guidance is $750 million–$850 million, reflecting normalization after asset sales and a conservative approach due to government transitions.

• 2025 adjusted EBITDA guidance is $150 million–$200 million, with net income forecasted at $16 million–$70 million.

• Adjusted gross margin expected to expand to 48%–51% in 2025.

• Q1 2025 revenue expected to be $200 million–$240 million, indicating a strong start.

• Guidance will be updated quarterly; up to $50 million in milestone payments from Bavarian Nordic anticipated.